On March 19, 2025, the Food and Drug Administration officially approved pembrolizumab (Keytruda, Merck) to be used along with trastuzumab and chemotherapy that includes fluoropyrimidine and platinum f...
Gene Therapy for Gaucher’s Disease in ChinaGaucher's disease is a rare inherited condition that happens when the body doesn't have enough of the glucocerebrosidase (GBA) enzyme, leading to harmful f...
Gene Therapy for Wilson's Disease in China Introduction Wilson’s disease is a rare genetic disorder that causes excessive copper accumulation in the liver, brain, and other vital organs. With...
Gene Therapy for Phenylketonuria in China: A Breakthrough Treatment IntroductionPhenylketonuria (PKU) is a rare genetic disorder that affects the body's ability to break down phenylalanine (Phe), an ...
On January 17, 2025, the Food and Drug Administration sanctioned datopotamab deruxtecan-dlnk (Datroway, Daiichi Sankyo, Inc.), a Trop-2-targeted antibody and topoisomerase inhibitor conjugate, for adu...
IntroductionLiver transplant surgery has seen tremendous progress in the last few decades, transforming the therapeutic possibilities of patients with end-stage liver disease, acute liver failure, and...
On December 18, 2024, the Food and Drug Administration sanctioned ensartinib (Ensacove, Xcovery Holdings, Inc.) for adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or ...
On December 13, 2024, the Food and Drug Administration sanctioned cosibelimab-ipdl (Unloxcyt, Checkpoint Therapeutics, Inc.), a programmed death ligand-1 (PD-L1) inhibiting antibody, for adults with...
On December 4, 2024, the Food and Drug Administration sanctioned durvalumab (Imfinzi, AstraZeneca) for adults with limited-stage small cell lung cancer (LS-SCLC) whose condition remains stable after...
On December 4, 2024, the Food and Drug Administration granted accelerated approval to zenocutuzumab-zbco (Bizengri, Merus N.V.) for use in adults with specific conditions.Patients with advanced, unr...